Episode Overview
Epilepsy therapy innovations start with an idea. So how does it go from that to a device that can be safely used in patients? In this episode of Seizure Diaries, our conversation is centered around the medical device regulatory process, offering a behind-the-scenes look at how safety, evidence, and patient protection guide every step of development.
Joining the conversation is Tim Marjenin, Vice President and Head of Neurology Regulatory Affairs at MCRA. Drawing on his experience at the U.S. Food and Drug Administration, he shares insight into the regulatory landscape and how it intersects with clinical research.
Listeners are introduced to the structure of medical device regulation in the United States, including how laws, FDA regulations, and guidance documents shape the pathway for bringing new technologies to market. The discussion explains device classifications, the unique Humanitarian Device Exemption pathway, and the collaborative relationship between companies, regulators, and clinical experts. Together, these elements illustrate the extensive planning, testing, and documentation required to demonstrate that a device is safe and effective.
Key takeaways emphasize the central role of risk-benefit evaluation, the multidisciplinary teams involved in reviewing devices, and the importance of communication and transparency, especially for families considering participation in clinical trials.
The episode highlights how rigorous oversight and thoughtful decision-making aim to ensure that new therapies are developed responsibly while maintaining a strong focus on patient well-being.
Listeners will hear:
- How a medical device moves from concept to regulatory approval
- The role of Congress, the FDA, and guidance documents in device oversight
- Differences between device classes and what they mean for safety requirements
- What the Humanitarian Device Exemption pathway is and when it’s used
- How FDA review teams evaluate safety, effectiveness, and risk-benefit balance
- Why strong communication between companies, regulators, and families matters
- Considerations for parents and caregivers when evaluating clinical trial participation
More about Cadence Neuroscience:
Cadence Neuroscience is currently developing an investigational BTS [Biomarker Targeted Stimulation] device therapy for the treatment of drug-resistant focal epilepsy, based on pioneering work performed by researchers at Mayo Clinic. Learn more at cadenceneuro.com.
This episode focuses on clinical experience and research insights. While no specific studies were cited, the organizations and technologies below provide helpful context for listeners who want to learn more.
Resources & Links Mentioned in This Episode
Episode Transcript
Tim Marjenin 0:00
I personally cannot imagine being in the position that a parent would be where they are having to make a decision to get an active, implantable medical device for their child to treat something like drug-resistant epilepsy.
Kent Leyde 0:21
I’m Kent Leyde, CEO of Cadence Neuroscience.
Doug Sheffield 0:23
And I’m Doug Sheffield, Chief Scientific Officer.
Kent Leyde 0:26
You’re listening to Seizure Diaries, where we explore all things epilepsy and explore the latest developments in epilepsy science and therapy.
Doug Sheffield 0:33
Together, and with expert guests, we discuss the impact of epilepsy and the work being done by Cadence Neuroscience and others, with the ultimate goal that every person lives a seizure-free life. Welcome.
Kent Leyde 0:51
Well, welcome everybody to our next episode of Seizure Diaries. We’re very pleased to introduce you to our guest, Tim Marjenin. Hey, Tim.
Tim Marjenin 0:58
Hey, everybody.
Kent Leyde 0:59
Tim, why don’t we get underway by having you introduce your yourselves to us and our audience?
Tim Marjenin 1:05
Sure. So my name is Tim Marjinen, and I’m the Vice President and Head of Neurology Regulatory Affairs at a company called MCRA, which is MCRA, an IQVIA business. So I am in the world of regulatory consulting for FDA, working on medical devices…
Kent Leyde 1:25
Which is where I first got to know you.
Tim Marjenin 1:26
Yeah, it’s been quite, been quite some time that we’ve been working together.
Kent Leyde 1:30
So Doug and I were talking about things that our listeners would benefit from, trying to get them a better feel for this interesting world of neuromodulation and how it relates to epilepsy therapy and, and also the real responsibility we feel for patients and why we want to do things right. And I think a lot of people don’t really understand how regulated the medical device business is and the important role that FDA plays in protecting the public interest and helping us device manufacturers maintain, really, the world’s highest level of quality for medical devices. So we’re hoping with this episode to give people a bit of a tops down understanding of how this part of the medical device ecosystem works, and the kinds of things that you do to make sure that devices are safe.
Tim Marjenin 2:25
Sure. So obviously, we only have about an hour in this podcast to get through all of this, but yeah, I can definitely provide some of the high-level details about it. Let’s start off with the top level of where all this kind of originates. So Congress gets together and they, and they write all the laws for the, for the country. And so part of that is writing the Food, Drug and Cosmetic Act, which also covers medical devices. And then FDA comes in and says, All right, we need to interpret what Congress was, was saying, and we, and they do that through regulations.
Kent Leyde 3:07
And Congress doesn’t give you a whole lot to work with, right? I mean, there the actual law is, is, like, a few pages, right? It’s just not very long.
Tim Marjenin 3:16
Yeah, there’s, there’s less to it than you would hope, but that’s where the regulations come into play, and it does give a lot more detail regarding what is necessary during the various stages of the process. And when you think about device regulations, certainly there are lots of things related to processes, like the process for getting a clinical study up and running, or the documentation that’s necessary as part of just being a device manufacturer, and the type of information you need to have as part of your quality system. And then they actually take it a step further by issuing what are called guidance documents, and those help provide even more detail than what was in the regulation. Maybe there might be something that’s very cross cutting and applies to lots of different device types, or maybe it’s something that’s very narrowly focused on one particular device type and the type of information that might be needed, either for clinical study or for some type of non-clinical testing. So there’s a lot of information that’s out there with respect to how to study your device, how to get it on the market, what are the types of things you need to do once it’s on the market.
Kent Leyde 4:37
Typify a FDA guidance document for the audience.
Doug Sheffield 4:41
The cyber security thing is a new one. We’ve been doing this now for 20 plus years, and all of a sudden, cyber security is front and center.
Tim Marjenin 4:49
Here are the things you need to think about when you are designing a medical device and you have cyber security considerations. So, It’s going to go into a good amount of detail. Maybe there will be some examples, depending on what type of guidance document it is, just helping, helping companies better understand. Here are the responsibilities that you have. Here’s the documentation that you need to create and provide and maintain, and all of that…
[MUSIC]
Doug Sheffield 5:24
We made a decision not to invest heavily internally with regulatory experts but to find experts outside. A small company like us can’t stay on top of all the details and so. Can you share a little bit about that? Your thought process on what you needed to build in your organization, and which was a big part of attracting us to work with you.
Tim Marjenin 5:47
What we have here is a group that, that has a lot of therapy-specific expertise. So, the, the team that I was leading when I was at FDA as a manager covered the types of devices that Cadence is, is working on: Deep Brain Stimulation devices among them, epilepsy being among the different intended uses that, that my team covered. So in addition to those different therapy specializations, MCRA’s also got in, within the regulatory team, a lot of additional expertise when it comes to things like bio compatibility, cyber security, software, digital just, digital health more broadly. And so that we’re able to provide a lot of different consulting services for companies who are looking to get into this space, we can help provide a lot of the, the strategic considerations that’ll help get companies off the ground so that they can actually start studying the device here in the United States.
Doug Sheffield 6:52
Way before you get to all the guidance documents and the nitty gritty, there are different paths to getting approval for a new therapy, just determining that path. And we picked a very unique path of an HUD/HDE and how do you begin? I mean, on this journey, if you pick the wrong path or a sub-optimal path, it’s not very efficient. So, what are those paths?
Kent Leyde 7:20
I want to amend your request, Doug. Remember Schoolhouse Rock, Tim? How a like, like, how a bill becomes a law. So tell us how, a how an idea becomes a medical device. You don’t have to sing it, though.
Tim Marjenin 7:35
There’s a lot that goes into figuring out where your device falls, how, how it’s classified. Ultimately, what, what FDA is trying to do when they’re looking at a medical device, you’re going to be in one of three classes. You think about something like a Band-Aid. That’s class one. It’s the lowest risk. A class two device is something that’s going to have more risk involved, that could even be an implant sometimes. So things like an aneurysm coil, for instance, or a shunt for treating hydrocephalus, those are actually class two devices, so there’s more documentation that’s involved with that.
Tim Marjenin 8:17
You don’t necessarily have to submit anything for the Band-Aid, but you will have to submit something for the shunt or for the aneurysm coil. And then you have the class three devices, which are the ones with the highest risk. So, very greatly simplifying all of this, something that is a brain stimulation system where you are actually putting electrodes in the brain to treat something, whether that be Parkinson’s disease, or essential tremor, epilepsy, those are all going to be class three devices.
Kent Leyde 8:53
Yep. Well, we want to make sure, we all want to make sure those are done right. Those are, so that’s why FDA gives it that high classification, that ensures that it’s going to get a whole lot of attention.
Tim Marjenin 9:04
When you’re a class three device, there is certain things that you will have to send in that you just don’t have to do with a class two device. Now, Cadence, as Doug was saying, took a unique approach with this, and they said that they will want to go for something called a Humanitarian Device Exemption. The interesting thing about this is that it’s not actually class one, two or three.
Tim Marjenin 9:32
It is a humanitarian use exemption classification. It’s kind of its own little carve out. And what’s unique about it is that it’s for you, you sometimes hear about things like orphan drugs for smaller populations. Things that don’t, that don’t really have a high incidence rate. So the Humanitarian Device Exemption is the device equivalent of that. If you have 8,000 or fewer patients per year in the United States who have an incidence of a particular disease or condition, then you can apply for something called a humanitarian use designation.
Tim Marjenin 10:15
Once you get that designation, you are allowed to submit that Humanitarian Designation Exemption submission. Once you get that approved, it does allow you to market the device in the United States. And as part of that, you’re going to have to collect a lot of evidence related to how the device performs. Is it going to be biocompatible? Is it going to be sterile? What does the electrical safety look like for a device like Cadence’s that has a battery? They want to know about battery safety. They want to know about software and cyber security.
Tim Marjenin 10:49
There’s a whole laundry list of things that you need to do and you need to collect. And then you have a clinical study. And so collecting all of that information, sending all of that in alongside manufacturing information, that all gets wrapped up into this massive collection of electronic documents that a group at FDA is going to review. And along the way, they may have questions, the company will address those, and then at the end of the day, we’re aiming for approval of the HDE so that Cadence can begin marketing the thing.
Kent Leyde 10:54
Just to scale some of these terms for people, HUD application you mentioned, which we filed some years ago. Ours was the size of an old-fashioned phone book, roughly, just the biocompatibility test plan. Just the plan is something like 400 pages long, but this translates into a huge amount of work, millions and millions of dollars of work, and years of work, and every step is planned, proceduralized in the form of protocols and then reported on in terms of test results. So it really is a pretty impressive set of documentation you put together to show that you followed a rigorous process.
Tim Marjenin 11:22
And yet that’s not even the full extent of everything that you have.
Kent Leyde 11:45
Yes.
Tim Marjenin 11:45
So for instance, CDRH is not like they don’t look at source code for software.
Kent Leyde 9:04
Yeah.
Tim Marjenin 10:36
What they’re really interested to know is, does it work? Does it do the thing that it is supposed to be doing, and can it do it safely? So there are different consensus standards that have been established, and like we talked about earlier, guidance documents, things that outline the types of testing that companies need to do for a device like Cadence’s to kick the tires on it, for lack of a better word, to make sure that it’s doing things properly. And so that way, they don’t have to get into the source code for the software because they have enough confidence based on the testing plan that Cadence has that everything is going to be operating the right way.
[MUSIC]
Doug Sheffield 13:11
In our discussions with FDA about, you know, the HUD and the HDE, there was a lot of encouragement, and that’s the word I would use, that we consider a pediatric indication, a side of FDA that I saw for the first time. You know, it wasn’t just the reviewing team, but there’s this group that is encouraging companies to develop therapies for children. Can you just share a little bit about that? I think our listeners would would like to hear that. I know I was encouraged by it.
Tim Marjenin 13:38
Yeah, and I don’t remember the specific name of the group, but I remember when I was there, there was a lot of interest, and it sounds like there continues to be a lot of interest in encouraging companies to pursue pediatric indications.
Doug Sheffield 13:53
And we needed that, you know, it’s a small company, you know, it’s a lot to do, even though they’re encouraging pediatric indications, doesn’t mean the work is less. Doesn’t mean that the shortcuts on safety and design, you know, providing what FDA needs, but it was encouraging to us because of, there are some benefits, right?
Tim Marjenin 14:12
There can be some benefits. Even outside of the HDE pathway, if you’re pursuing a purely pediatric indication, that might reduce some of the expense that, that you’re going to have when it comes to the user fees and that you might need to pay in order to get your, your marketing application reviewed. In terms of the requirements and everything, as, Doug, you were saying, yeah, it doesn’t, it doesn’t give you any, any shortcuts. Sure there may be some very specific incentives for the company to pursue a pediatric indication, but if anything, the level of rigor in the review is probably going to be increased whenever you’re talking about a pediatric population, just because…
Kent Leyde 14:59
Exactly.
Tim Marjenin 14:59
The review teams are going to be very concerned about any time that you’re looking to put a stimulator, implant electrodes in a child’s brain to, even if it’s to treat something like epilepsy, which, again, if you’re talking about drug-resistant epilepsy, you’ve exhausted a lot of your, your existing options. They’re going to take that very seriously when they’re evaluating things.
Kent Leyde 15:23
Yep, as they should.
Doug Sheffield 15:25
As they should. It brings me to one point I think our listeners would love to hear, I think that’s been a key for Kent and I in the company, is to develop a relationship with the FDA to understand what we really need to do and what they really want and what they need.
Tim Marjenin 15:40
If we pull back the curtain, just, just a little bit. Obviously, we’re talking about medical devices here. So we’re talking about the Center for Devices and Radiological Health. When you’re talking about CDRH, they’re the ones evaluating medical devices. Everything is kind of categorized by intended use. So you have a number of different offices within CDRH that look at these individual types of devices.
Tim Marjenin 16:10
So this Office of Health Technology 5 happens to be the one that covers neurological and physical medicine devices. So that’s the one that Doug and Kent are working with. There are two divisions within that. One covers neuro diagnostic devices and neurosurgical and neuro interventional. And on the other side, you have the one that has the neuromodulation and the physical medicine devices. So that’s again, drilling down one additional level and then one final level, you have four teams within that division.
Tim Marjenin 16:48
So the one that I used to lead when I was there, and the one that Doug and Kent are still working with now, is the neurostimulation devices neurology team. It’s such a very inventive and creative name. And the way that companies will get their product assigned to a certain team is really by the intended use. So something like deep brain stimulation for whether it’s again, Parkinson’s or essential tremor or epilepsy, those are examples of devices that be would be reviewed by the team that I used to supervise.
Tim Marjenin 17:26
But it’s not as if all deep brain stimulation goes to that team. If it’s deep brain stimulation for depression, for instance, that’s going to go to a different team. What that means, though, is that once you are assigned to a team based on what your intended use is, you’re going to be working with that same team, and so, to Doug’s point, it is really important to establish a relationship with the team with which you’re working, because you’re going to be working alongside them for a number of years.
Tim Marjenin 17:58
So certainly, Cadence has been at this for a number of years already at this point. Having that relationship, establishing the good communication with the team, is just so critical. Because even if you know they’re not going to cut you any slack, because they’re not, at least you know that you can have a good dialog with them.
Kent Leyde 18:18
Yeah.
Tim Marjenin 18:19
Have a productive discussion.
Kent Leyde 18:21
Yeah, and these are complex devices. There’s a lot of, you know, words and regulations and things for us to all reach a common understanding about, and that all requires a lot of communication.
Tim Marjenin 18:33
And part of the what’s really unique about CDRH, well, FDA in general. But again, if we’re focusing on CDRH, you think about it, you have a group of eight to 10 individuals, depending on what current, current staffing situation looks like on the team. They’re the only ones looking at any of these devices for the entire country. And the manufacturers who are submitting things to them, they’re they’re located anywhere in the world, really. The point is they want to get their device on the market in the United States.
Tim Marjenin 19:07
And for a brain stimulation device that’s treating epilepsy, this group is it. So they’re able to leverage a lot of knowledge that they’ve seen across a number of different applications. And as you were saying, like, even, even if you’ve been in the field for a long period of time, you don’t necessarily have that same level of visibility on, on things as they do, which is great, because it means they’re able to help you understand, okay, we like we have these suggestions for the testing that you might be doing. And here’s, here’s why we think you should be doing certain things a certain way.
Kent Leyde 19:49
And you can tell that the team is very aware of any problems the device might have had, or if there’s been any, you know, any kind of issues or things like that to be aware of. They really have the great background for this.
[MUSIC]
Kent Leyde 20:08
Could we shift gears just a little bit? And let’s talk about the people at FDA doing this work. Strikes me that everyone I’ve met, they’re all very concerned about patient safety. They’re presented with a really challenging task. This application rolls in, has thousands and thousands of pages, and at the end of the day, it’s their responsibility to make sure that before they say yes, that they’re satisfied and convinced that things have been done correctly and appropriately. So, what kind of person do you see working on these assets at FDA?
Tim Marjenin 20:43
The type of team that, that you’re working with is going to have some number of engineers, likely biomedical engineers, but there may be some electrical engineers or others. There may be a toxicologist or a chemist, there’s going to be a clinician. And just like I’m not the only one at MCRA who’s doing all the work for Cadence, there’s not one person who’s going to be looking at everything on the review team.
Kent Leyde 21:16
A lot of expertise represented across a broad set of fields.
Tim Marjenin 21:22
Right. The way that it works is that a submission will come in, so Cadence wants to submit something to FDA for review. So in this case, we’re talking about an investigational device exemption. It’s going to go to the assistant director, who’s going to assign it to a lead reviewer.
Kent Leyde 21:39
They kind of quarterback the application, right?
Tim Marjenin 21:42
Yes, they’re often an engineer. Could be a scientist of some type, but they’re going to be coordinating with the rest of the team. If there is biocompatibility information, OK, we’re going to get a biocompatibility person to look at that. Sterility, same thing, electrical safety, electromagnetic compatibility, battery safety, all of those different things they’re all going to get assigned to different individuals.
Tim Marjenin 22:07
So, yes, 10,000 pages and getting through all of that for one person is a pretty monumental task. However, that’s not actually the case. You’re splitting things up, and you’re making sure that each individual person is looking at their respective pieces, they’re trying to determine is all the information there? Does it meet what we would expect for this type of device and this type of testing?
Tim Marjenin 22:32
if it is, if it does, great, if not, and we have questions about it, well, that’s what we’ll send over to the company, and we’ll explain to them here’s what we think we need, why we think we need it, and then you kind of start the process over again. What’s really important to think about is this is the type of project that a company will work, be working on for months, if not years. When a company sends their IDE over to CDRH for review, they have a grand total of 30 calendar days to look at it.
Kent Leyde 23:04
Right.
Tim Marjenin 23:05
They have to get through all of those 10,000 pages of information, understand all those 10,000 pages of information, discuss it amongst themselves, figure out whether they have questions, and ultimately have all that wrapped up by the end of 30 days. So the lead reviewer isn’t actually making the decision. All they’re doing is making a recommendation. It then it goes up to their manager, who is as the assistant director decides, well, do I agree with this recommendation? And if so, they move it up the chain to the to the final stop, which is, generally speaking, the Division Director, that is the individual who’s actually making the decision on whether or not to approve this study.
Doug Sheffield 23:50
Can I just jump in real quick? Because one of the things I’ve learned in my decades in this space, at the end, everything has risks and safety is not an absolute. There’s a balancing act that our review team is looking at in terms of risk benefit and…
Kent Leyde 24:05
Judgment is required, at the end of the day.
Doug Sheffield 24:08
Judgment’s required. Can you share a little bit about, again that risk/benefit equation?
Tim Marjenin 24:14
I’m in the position of helping companies write those arguments regarding why they believe the benefits outweigh the risks. Ultimately, when you’re thinking about medical devices, FDA saying that something can be on the market here comes down to the idea that it has demonstrated a reasonable assurance of safety and effectiveness. Seems simple enough, right?
Tim Marjenin 24:40
Except it’s a reasonable assurance of safety is one concept, and a reasonable assurance of effectiveness is another, and both of them are defined in the regulations. But in plain language, the idea is that for a reasonable assurance of safety, it means that when you’re using a device properly, the probable benefits to health, outweigh the probable risks to health and that there is an absence of unreasonable risk. So to say that a device is safe, it doesn’t mean that it is risk-free. A deep brain stimulation system is not a risk-free device.
Tim Marjenin 25:17
You are undergoing a surgical procedure, so the idea that you have probable benefits outweighing probable risks, it’s very much an apples to oranges comparison. On the one hand, you are trying to say, do we have clinical benefit, and do we have enough information to say that we really believe that, that the benefit is real, are how confident are we in those benefits? And then the same thing on the risk side, how can we characterize the risks and how confident are we about the expected rates, for instance? And then you try and make the argument that the benefits outweigh the risks, and FDA is ultimately the arbiter of whether they think that’s true.
Doug Sheffield 26:04
So if I’m a parent of a child and I’m considering an implantable device for my child that has epilepsy, I can be assured that FDA has, has spent a lot of time looking at that balance of potential risks and potential benefit. I think, for parents considering a therapy for the child, that’s important for them to know that this is the heart of the review of the technology that we want to assess in a clinical study.
Tim Marjenin 26:36
Yeah, the review teams, they spend a lot of time thinking about these things. And again, it’s very much a team effort, and anybody who identifies issues that they believe need to be resolved, they’re going to speak up about it. Even if everything else looks okay, if there are significant safety concerns with one aspect of the testing or one aspect of the clinical study, that’s enough for them to say no.
Kent Leyde 27:03
Yeah, we should all have some confidence in the system. I think it works well. Back way off and look all around the globe at different nations’ approaches for approving medical devices and making sure things are safe. I think it’s interesting to note that devices that come from the United States are considered to be the best of the best and the safest of the safest. And part of that’s because we’ve got a regulatory system that’s very thorough and works and is staffed by very expert people who care about their job, and there’s not not a lot of gaps in that net.
Doug Sheffield 27:36
What’s the biggest takeaway you think, from this discussion, for a family who are considering allowing their child to be part of a trial?
Tim Marjenin 27:43
I personally cannot imagine being in the position that a parent would be where they are having to make a decision to get an active, implantable medical device for their child to treat something like drug-resistant epilepsy.
Kent Leyde 28:01
Such a challenging scenario, isn’t it?
Tim Marjenin 28:03
It really is.
Kent Leyde 28:04
Yeah.
Tim Marjenin 28:05
And as a parent myself, I just, I cannot fathom what that feels like.
Kent Leyde 28:11
Yeah.
Tim Marjenin 28:11
I think when it comes to anybody, and certainly Cadence, but any, any medical device company that, that I’ve been working with over the years, they’re all trying to do the right thing. When you think about what FDA is doing, they want to get to the best answer, and they’re going to ask a lot of questions. As a parent or as a caregiver, you need to put yourself in the same position. You need to ask all of the questions that you have.
Tim Marjenin 28:39
Don’t be afraid to ask all of the questions. You’re establishing a relationship with them, because you’re going to be working with them for a long time if you’re going to be in this study. Ultimately, you’re doing this to try and benefit the child, and you want to make sure that you have a good understanding going into this of what this whole experience and journey is going to be like. You need to be willing to ask all of the hard questions and try and make sure that you know, that you understand everything to the best of your ability, because it is a very big decision to be making.
[MUSIC]
Kent Leyde 29:15
And it’s our job to be forthcoming and transparent and support that discussion.
Doug Sheffield 29:20
From my view, Kent and Tim, I can’t imagine a better discussion.
Kent Leyde 29:24
It’s been great.
Doug Sheffield 29:24
And I appreciate your time. I think this is going to be really helpful for our journey, so definitely appreciate your thoughts.
Tim Marjenin 29:32
Yeah, I’m happy to help.
Kent Leyde 29:35
Thanks so much for joining us for Seizure Diaries.
Doug Sheffield 29:37
We hope you find these conversations helpful. If you do, we hope you’ll consider sharing our podcast with others.
Kent Leyde 29:44
Everybody says it, but it really does help others to discover the show when you rate, review, and share. You can find Seizure Diaries wherever you listen to podcasts.
Doug Sheffield 29:53
We’ll see you next time.
Kent Leyde 29:54
You’re getting better at this.
Doug Sheffield 29:56
You say that every time.